Teva has raised its 2026 revenue forecasts for all three of its brands AUSTEDO, AJOVY and UZEDY, after reporting third-quarter revenue of $4.39bn and earnings of $0.86 a share.

AUSTEDO is now expected to bring in $2.55bn-$2.65bn, from $2.45bn-$2.60bn. For AJOVY the range is $930m-$960m, from $850m-$870m. UZEDY moves to $290m-$310m, from $270m-$290m.

Richard Francis, Teva's chief executive, said 33% local-currency growth across the three brands, together with margin expansion and cash flow, gave the company the confidence to raise. The trend is not new. In 2025, AUSTEDO global revenues rose 34% and AJOVY grew 30%.

The raise matters because the group targets lean on it. Teva's outlook now calls for total revenue of $16.7bn-$17.0bn, non-GAAP operating income of $3.8bn-$3.9bn, non-GAAP diluted earnings of $1.92-$2.11 a share and free cash flow of $2.1bn-$2.4bn. Hitting the upper ends of the earnings and cash ranges would need the same momentum, so any slowdown in the three brands would show there first.

© Raydn · raydn.us